Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | Novel targeted therapies for the treatment of BPDCN

Muzaffar Qazilbash • 30 Jul 2024
EHA 2024
Blastic Plasmacytoid Dendritic Cell Neoplasm Rare Diseases Azacitidine CAR-T Decitabine Pivekimab sunirine Tagraxofusp Venetoclax

Muzaffar Qazilbash, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses novel targeted therapies for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), mentioning the FDA-approved agent tagraxofusp and the treatment options currently in development. Dr Qazilbash highlights that the only curative treatment strategy currently available for patients is allogeneic stem cell transplantation (alloSCT). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research Funding: Sanofi, Janssen, Angiocrine; Advisory Board: Sanofi.

More from Muzaffar Qazilbash

The trends in outcomes after upfront autoSCT for multiple myeloma over three decades
2:52
The trends in outcomes after upfront autoSCT for multiple myeloma over three decades
Muzaffar Qazilbash • 7 Dec 2024
Assessing the outcomes of patients with myeloma with deletion 1p following autoSCT
2:35
Assessing the outcomes of patients with myeloma with deletion 1p following autoSCT
Muzaffar Qazilbash • 7 Dec 2024
Impact of ethnicity on outcomes of high-dose chemotherapy + upfront autoSCT in patients with myeloma
2:56
Impact of ethnicity on outcomes of high-dose chemotherapy + upfront autoSCT in patients with myeloma
Muzaffar Qazilbash • 7 Dec 2024
The long-term outcomes of consolidative alloSCT for BPDCN
3:36
The long-term outcomes of consolidative alloSCT for BPDCN
Muzaffar Qazilbash • 30 Jul 2024

Related Videos

BPDCN: unmet needs, CD123-targeted therapies and novel targets
15:50
BPDCN: unmet needs, CD123-targeted therapies and novel targets
Naveen Pemmaraju • 19 Sep 2026
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
2:19
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
1:39
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
Elena Zamagni • 25 Sep 2026
Anselamimab in AL amyloidosis: combining and sequencing with plasma cell-directed treatment
2:14
Anselamimab in AL amyloidosis: combining and sequencing with plasma cell-directed treatment
Ashutosh Wechalekar • 9 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals